CJC-1295 Research Peptide

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone designed for prolonged activity.

• The Drug Affinity Complex, or DAC, enables covalent association with circulating albumin and extends exposure.
• CJC-1295 without DAC and modified GRF 1-29 are often used as market labels, but they should not be assumed to be the same molecule as DAC-containing CJC-1295.

CJC-1295 acts through the GHRH receptor on pituitary somatotroph cells.

• Early controlled studies in healthy adults measured sustained changes in growth hormone and IGF-1 while preserving pulsatile GH secretion.
• Research questions include duration, albumin binding, endocrine markers, sequence identity, stability, and comparisons with ghrelin-receptor agonists.
• The exact sequence and conjugation state determine which evidence is relevant.

Human evidence is limited to small early studies and does not establish broad clinical use.

• CJC-1295 is not generally approved as a therapeutic medicine.
• Online “DAC” and “no-DAC” labels require analytical confirmation because naming practices are inconsistent across suppliers.